Global investment giant Ardian has reinvested in Italian pharmaceutical commercialisation business Neopharmed.
The deal comes four years after Ardian picked up a stake in the business, which was then the therapeutics unit of Italian drugmaker Mediolanum Farmaceutici.
Neopharmed’s buy-and-build strategy since Ardian’s investments has seen it bolt-on six businesses, and reach revenues of €250m.
Read more: Alt Assets
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.